Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Puma Biotechnology (PBYI)
NASDAQ:PBYI
PBYI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.23 - $7.15
Previous CloseN/A
Volume522.58K
Average Volume (3M)454.43K
Market Cap
$143.34M
Enterprise Value$115.04M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)6.1
Beta1.29
Next Earnings
Feb 27, 2025EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.47
Shares Outstanding49,087,685
10 Day Avg. Volume228,624
30 Day Avg. Volume454,429
Standard Deviation0.23
R-Squared0.06
Alpha-0.00692
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.58
Price to Cash Flow (P/CF)3.20
P/FCF Ratio3.20
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.67
Enterprise Value/Ebitda2.36
Forecast
1Y Price Target
$7.00Price Target Upside141.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Puma Biotechnology News
PremiumCompany Announcements
Puma Biotechnology Reports Strong Q3 2024 Growth---
Bulls Say, Bears Say
Bulls Say
Earnings GuidanceManagement updated FY 2024 revenue guidance to include net product revenue of $187-190MM as well as royalty and license revenue to total $34-36MM.
Financial PerformancePuma reported Nerlynx sales of $56.1MM above consensus of $50MME.
Product DemandThe inclusion of Nerlynx in the updated NCCN Guidelines for Cervical Cancer as a treatment option signifies a potential increase in demand for the drug.
Bears Say
Cash PositionPuma ended Q3 with cash of $97MM and net cash of $19MM.
Company RisksThere are several potential risks associated with the company, including commercial, regulatory, development, manufacturing, financial, and liability risks.
Seasonal DemandFor Q4, management noted that Nerlynx demand tends to be soft due to the holiday season.
---
Ownership Overview
32.12% Insiders
12.21% Mutual Funds
13.07% Other Institutional Investors
32.04% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PBYI FAQ
What was Puma Biotechnology’s price range in the past 12 months?
Puma Biotechnology lowest stock price was $2.23 and its highest was $7.15 in the past 12 months.
What is Puma Biotechnology’s market cap?
Puma Biotechnology’s market cap is $143.34M.
When is Puma Biotechnology’s upcoming earnings report date?
Puma Biotechnology’s upcoming earnings report date is Feb 27, 2025 which is in 5 days.
How were Puma Biotechnology’s earnings last quarter?
Puma Biotechnology released its earnings results on Nov 07, 2024. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.333 by $0.077.
Is Puma Biotechnology overvalued?
According to Wall Street analysts Puma Biotechnology’s price is currently Undervalued.
Does Puma Biotechnology pay dividends?
Puma Biotechnology does not currently pay dividends.
What is Puma Biotechnology’s EPS estimate?
Puma Biotechnology’s EPS estimate is 0.09.
How many shares outstanding does Puma Biotechnology have?
Puma Biotechnology has 49,087,685 shares outstanding.
What happened to Puma Biotechnology’s price movement after its last earnings report?
Puma Biotechnology reported an EPS of $0.41 in its last earnings report, beating expectations of $0.333. Following the earnings report the stock price went down -4.95%.
Which hedge fund is a major shareholder of Puma Biotechnology?
Currently, no hedge funds are holding shares in PBYI
---
Puma Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (141.38% Upside)
$7.00 (141.38% Upside)
Blogger Sentiment
Bullish
PBYI Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.99%
12-Months-Change
Fundamentals
Return on Equity
42.32%
Trailing 12-Months
Asset Growth
8.41%
Trailing 12-Months
Company Description
Puma Biotechnology
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
---
PBYI Company Deck
---
PBYI Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Q3 2024 presented a strong financial performance with substantial increases in both revenue and net income, driven by NERLYNX sales and significant royalty revenue growth. However, there were concerns about flat total prescriptions and a year-over-year decrease in bottle sales. Despite these challenges, the company's global expansion and strategic initiatives suggest a positive outlook.Read More>---
PBYI Stock 12 Month Forecast
Average Price Target
$7.00
▲(141.38% Upside)
Technical Analysis
Best Analysts Covering PBYI
1 Year
1 Year Success Rate
16/27 ratings generated profit
1 Year Average Return
+5.76%
reiterated a buy rating 2 months ago
Copying Edward White's trades and holding each position for 1 Year would result in 59.26% of your transactions generating a profit, with an average return of +5.76% per trade.
---